Common Contracts

EX-2.1 2 d629511dex21.htm EX-2.1 [***] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange...

Asset Purchase Agreement • May 5th, 2020 • Delaware

• Contract Type
  Asset Purchase Agreement
• Filed
  May 5th, 2020
• Jurisdiction
  Delaware

THIS ASSET PURCHASE AGREEMENT, dated as of August 20, 2018 (this “Agreement”), is made by and among Sierra Oncology, Inc., a Delaware corporation (“Buyer”), YM Biosciences Australia Pty Ltd, a company organized under the laws of Australia (“Seller”), and Gilead Sciences, Inc., a Delaware corporation (“GSI”), solely for purposes of Section 7.1. Seller, GSI and Buyer may hereinafter be referred to individually as a “Party” and, collectively, as the “Parties”.

ASSET PURCHASE AGREEMENT by and among SIERRA ONCOLOGY, INC., YM BIOSCIENCES AUSTRALIA PTY LTD, and GILEAD SCIENCES, INC. (Solely For Purposes of Section 7.1) Dated as of August 20, 2018

Asset Purchase Agreement • November 8th, 2018 • Sierra Oncology, Inc. • Pharmaceutical preparations • Delaware

• Contract Type
  Asset Purchase Agreement
• Filed
  November 8th, 2018
• Company
  Sierra Oncology, Inc.
• Industry
  Pharmaceutical preparations
• Jurisdiction
  Delaware

THIS ASSET PURCHASE AGREEMENT, dated as of August 20, 2018 (this “Agreement”), is made by and among Sierra Oncology, Inc., a Delaware corporation (“Buyer”), YM Biosciences Australia Pty Ltd, a company organized under the laws of Australia (“Seller”), and Gilead Sciences, Inc., a Delaware corporation (“GSI”), solely for purposes of Section 7.1. Seller, GSI and Buyer may hereinafter be referred to individually as a “Party” and, collectively, as the “Parties”.